Opgenorth TJ - Search Results

1

Endothelin A receptor blockade alleviates hypertension and renal lesions associated with chronic nitric oxide synthase inhibition.

Verhagen AM, Rabelink TJ, Braam B, Opgenorth TJ, Gröne HJ, Koomans HA, Joles JA. Verhagen AM, et al. Among authors: opgenorth tj. J Am Soc Nephrol. 1998 May;9(5):755-62. doi: 10.1681/ASN.V95755. J Am Soc Nephrol. 1998. PMID: 9596072

2

Angiotensin blockade reverses hypertension during long-term nitric oxide synthase inhibition.

Pollock DM, Polakowski JS, Divish BJ, Opgenorth TJ. Pollock DM, et al. Among authors: opgenorth tj. Hypertension. 1993 May;21(5):660-6. doi: 10.1161/01.hyp.21.5.660. Hypertension. 1993. PMID: 7684026

3

Selective endothelin-A versus combined endothelin-A/endothelin-B receptor blockade in rat chronic heart failure.

Mulder P, Boujedaini H, Richard V, Derumeaux G, Henry JP, Renet S, Wessale J, Opgenorth T, Thuillez C. Mulder P, et al. Circulation. 2000 Aug 1;102(5):491-3. doi: 10.1161/01.cir.102.5.491. Circulation. 2000. PMID: 10920058

4

Role of endothelin ET(A) receptors in the hypertension produced by 4-day L-nitroarginine methyl ester and cyclosporine treatment.

Pollock DM, Polakowski JS, Opgenorth TJ, Pollock JS. Pollock DM, et al. Among authors: opgenorth tj. Eur J Pharmacol. 1998 Apr 3;346(1):43-50. doi: 10.1016/s0014-2999(98)00043-0. Eur J Pharmacol. 1998. PMID: 9617750

5

Different contributions of endothelin-A and endothelin-B receptors in the pathogenesis of deoxycorticosterone acetate-salt-induced hypertension in rats.

Matsumura Y, Hashimoto N, Taira S, Kuro T, Kitano R, Ohkita M, Opgenorth TJ, Takaoka M. Matsumura Y, et al. Among authors: opgenorth tj. Hypertension. 1999 Feb;33(2):759-65. doi: 10.1161/01.hyp.33.2.759. Hypertension. 1999. PMID: 10024341

6

Exaggerated vascular and renal pathology in endothelin-B receptor-deficient rats with deoxycorticosterone acetate-salt hypertension.

Matsumura Y, Kuro T, Kobayashi Y, Konishi F, Takaoka M, Wessale JL, Opgenorth TJ, Gariepy CE, Yanagisawa M. Matsumura Y, et al. Among authors: opgenorth tj. Circulation. 2000 Nov 28;102(22):2765-73. doi: 10.1161/01.cir.102.22.2765. Circulation. 2000. PMID: 11094045

7

Angiotensin II receptor blockade improves renal function in rats with reduced renal mass.

Pollock DM, Divish BJ, Polakowski JS, Opgenorth TJ. Pollock DM, et al. Among authors: opgenorth tj. J Pharmacol Exp Ther. 1993 Nov;267(2):657-63. J Pharmacol Exp Ther. 1993. PMID: 8246138

8

'Irreversible' endothelin-1 binding does not prohibit ABT-627 from reversing endothelin-1-induced effects.

Chiou WJ, Wessale JL, von Geldern T, Opgenorth TJ, Wu-Wong JR. Chiou WJ, et al. Among authors: opgenorth tj. J Cardiovasc Pharmacol. 2000 Nov;36(5 Suppl 1):S48-52. doi: 10.1097/00005344-200036051-00017. J Cardiovasc Pharmacol. 2000. PMID: 11078333

9

Increased susceptibility to deoxycorticosterone acetate-salt-induced hypertension in endothelin-B-receptor-deficient rats.

Matsumura Y, Kuro T, Kobayashi Y, Konishi F, Takaoka M, Wessale JL, Opgenorth TJ, Gariepy CE, Yanagisawa M. Matsumura Y, et al. Among authors: opgenorth tj. J Cardiovasc Pharmacol. 2000 Nov;36(5 Suppl 1):S86-9. doi: 10.1097/00005344-200036051-00028. J Cardiovasc Pharmacol. 2000. PMID: 11078344

10

The orally active nonpeptide endothelin A-receptor antagonist A-127722 prevents and reverses hypoxia-induced pulmonary hypertension and pulmonary vascular remodeling in Sprague-Dawley rats.

Chen SJ, Chen YF, Opgenorth TJ, Wessale JL, Meng QC, Durand J, DiCarlo VS, Oparil S. Chen SJ, et al. Among authors: opgenorth tj. J Cardiovasc Pharmacol. 1997 Jun;29(6):713-25. doi: 10.1097/00005344-199706000-00003. J Cardiovasc Pharmacol. 1997. PMID: 9234651

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

127 results

Search Page

Filters